Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCC-Reference-Cited by-同舟云学术

Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCC

Published:2016-05-20 Issue:8 Volume:15 Page:1988-1997
ISSN:1535-7163
Container-title:Molecular Cancer Therapeutics
language:en
Short-container-title:Mol Cancer Ther

Author:

Nakamura Yu,Togashi Yosuke,Nakahara Hirokazu,Tomida Shuta,Banno Eri,Terashima Masato,Hayashi Hidetoshi,de Velasco Marco A.,Sakai Kazuko,Fujita Yoshihiko,Okegawa Takatsugu,Nutahara Kikuo,Hamada Suguru,Nishio Kazuto

Funder

Japan Society for the Promotion of Science

Research Activity

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic implications of signaling pathways and tumor microenvironment interactions in esophageal cancer;Biomedicine & Pharmacotherapy;2024-07

2. Randomized phase II study of preoperative afatinib in untreated head and neck cancers: predictive and pharmacodynamic biomarkers of activity;Scientific Reports;2023-12-18

3. Randomized phase II study of preoperative Afatinib in untreated head and neck cancers: predictive and pharmacodynamic biomarkers of efficacy;2023-08-25

4. Potential use of EGFR-targeted molecular therapies for tumor suppressor CYLD-negative and poor prognosis oral squamous cell carcinoma with chemoresistance;Cancer Cell International;2022-11-15

5. An Unbiased Functional Genetics Screen Identifies Rare Activating ERBB4 Mutations;Cancer Research Communications;2022-01-07